|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 16, 2016 ) CNS disorders can affect either the brain or spinal cord, or both. CNS disorders are also called as neurological and psychiatric disorders. The major causes of CNS disorders are infections, trauma, degeneration, structural defects, tumors, autoimmune disorders, and stroke. A headache, muscle weakness, memory loss, impaired mental ability, and lack of coordination are few of the symptoms of CNS disorders.
Publisher's analysts forecast the global central nervous system (CNS) disorders therapeutics market to grow at a CAGR of 3.38% during the period 2016-2020.
For more information about this report: http://www.reportsweb.com/global-central-nervous-system-disorders-therapeutics-market-2016-2020
Covered in this report
The report covers the present scenario and the growth prospects of the global central nervous system (CNS) disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-labeled drugs used for the treatment of various CNS disorders including bipolar disorders, depression, epilepsy, PD, AD, Huntington's disease (HD), multiple sclerosis (MS), schizophrenia, attention-deficit hyperactivity disorder (ADHD), migraine, and anxiety.
The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
Publisher's report, Global Central Nervous System (CNS) Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- GlaxoSmithKline
- Pfizer
- Eli Lilly
- Janssen Pharmaceuticals
- Novartis
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001409111/sample
Other prominent vendors
- AB Science
- AbbVie
- Abital Pharma
- Acorda Therapeutics
- Active Biotech
- Adamas Pharmaceuticals
- Addex Therapeutics
- Akorn
- Alcobra
- Alexza Pharmaceuticals
- Alkermes
- Amarantus
- Aprecia Pharmaceuticals
- Archer Pharmaceuticals
- Astellas
- AstraZeneca
- Aurobindo Pharma
- Auspex Pharmaceuticals
- Avanir Pharmaceuticals
- Biscayne Pharmaceuticals
- Boehringer Ingelheim
- Cerecor
- Concordia
- Convergence Pharmaceuticals
- Curemark
- CURx Pharmaceuticals
- Dainippon Sumitomo Pharma
- Dart NeuroScience
- Delpor
- Desitin Arzneimittel
- D-Pharm
- Edgemont Pharmaceuticals
- Endo International
- E-Therapeutics
- Euthymics
- Evotec
- F. Hoffmann-La Roche
- Fabre-Kramer Pharmaceuticals
- Forum Pharmaceuticals
- Gedeon Richter
- Glenmark
- Grupo Ferrer Internacional
- GW Pharmaceuticals
- H. Lundbeck
- Hisamitsu
- Impax
- Insero Health
- INSYS Therapeutics
- Intellipharmaceutics
- Intra-Cellular Therapies
- Ipsen
- Kyowa Hakko Kirin
- Ligand Pharmaceuticals
- Lupin
- MarcoPolo Pharmaceuticals
- Marinus Pharmaceuticals
- Meda AB
- Merck
- Mitsubishi Tanabe
- MSI Methylation Sciences
- Mylan
- Naurex
- Neuralstem
- Neurelis
- Neurovance
- Nobelpharma
- Noven Pharmaceuticals
- Omeros
- Opexa
- Opko Health
- Orion
- Ophelia Pharmaceutical
- Otsuka Pharmaceuticals
- Palobiofarma
- Par Pharmaceuticals
- Pierre Fabre
- Prana Biotechnology
- Raptor Pharmaceutical
- Reviva Pharmaceuticals
- SAGE Therapeutics
- Sanofi
- SciFlour
- Sedor Pharmaceuticals
- Shire
- Siena Biotech
- SK Biopharmaceuticals
- SOM Biotech
- Somerset Pharmaceuticals
- STADA Arzneimittel
- Sun Pharmaceuticalc
- Sunovion Pharmaceuticals
- Supernus Pharmaceuticals
- Suven
- Takeda Pharmaceuticals
- Teva Pharmaceuticals
- Torrent Pharmaceuticals
- Tris Pharma
- Turing Pharmaceuticals
- UCB
- US WorldMeds
- Valeant Pharmaceuticals
- Zinfandel Pharmaceuticals
- Zogenix
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001409111/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
